Thalidomide in multiple myeloma

Biomedicine and Pharmacotherapy

Volumn 56, Issue 3, 2002, Pages 115-128

  Richardson, P ^a   Hideshima, T ^a   Anderson, K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anti angiogenesis; Immunomodulation; Myeloma; Thalidomide

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALLOPURINOL; ANGIOGENESIS INHIBITOR; CISPLATIN; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; LENALIDOMIDE; PHOSPHODIESTERASE IV INHIBITOR; SULFONAMIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; ERYTHEMA NODOSUM LEPROSUM; HUMAN; IC 50; IMMUNOMODULATION; MULTIPLE MYELOMA; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; TREATMENT OUTCOME;

EID: 0036227466     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(02)00168-3     Document Type: Article

References (92)

1. Thalidomide for resistant and relapsing myeloma
2. Management of multiple myeloma today
3. Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures
4. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients
5. Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM)
6. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
7. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
8. Thalidomide in dermatology. New indications for an old drug
9. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells
10. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
11. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
12. Thalidomide neurotoxicity
13. Non-myeloppressive therapy with BLT-DC (Biaxin, Low-dose thalidomide and dexamethasone) is highly active in Waldenstrom's macroglobunemia and myeloma
14. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF- alpha
15. Thalidomide is an inhibitor of angiogenesis
16. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
17. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
18. Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium
19. Continuous low dose Thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
20. Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: A phase II study
21. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
22. The metabolism of thalidomide: Some biological effects of thalidomide and its metabolites
23. The metabolic fate of thalidomide
24. Does thalidomide affect IL-2 response and production?
25. Randomized, phase II study of thalidomide in androgen-independent prostate cancer (AIPC)
26. Pharmacokinetics of thalidomide in an elderly prostate cancer population
27. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas
28. Thalidomide neuropathy: A clinical electrophysiological, and histological follow-up study
29. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
30. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications
31. Thalidomide on the comeback trail
32. Multiple myeloma: Increasing evidence for a multistep transformation process
33. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
34. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
35. Thalidomide in the treatment of erythema nodosum leprosum: With a note on selected laboratory abnormalities in erythema nodosum leprosum
36. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: Therapeutic applications
37. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
38. Thalidomide treatment of resistant or relapsed multiple myeloma patients
39. WAF1,CIP1 in human brain tumors
40. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506
41. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity
42. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
43. Anti-angiogenic therapy of human esophageal cancers with thalidomide in nude mice
44. Thalidomide and its immunomodulatory drug inhibit multiple myeloma cell growth and angionenesis in vivo
45. Malformations caused by drugs in pregnancy
46. The susceptible period for thalidomide malformations in man and monkey
47. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer
48. Thalidomide in rabbit semen
49. A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer
50. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
51. The saga of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies
52. Inhibition of IL-12 production by thalidomide
53. Thalidomide-effect on T cell subsets as a possible mechanism of action
54. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
55. Thalidomide: From tragedy to new drug discovery
56. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density (MVD) in bone marrow biopsies
57. Thalidomide and chemotherapy combination: Preliminary results of preclinical studies
58. Thalidomide and the immune system. simultaneous up- and down- regulation of different integrin receptors on human white blood cells
59. Deep venous thrombosis and thalidomide therapy for multiple myeloma
60. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
61. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients
62. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
63. Genetic determinants of p53-induced apoptosis and growth arrest
64. Thalidomide in the treatment of relapsed multiple myeloma
65. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
66. Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites
67. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
68. A phase I study of the safety and efficacy of CC5013 treatment for patients with relapsed multiple myeloma: Preliminary results
69. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
70. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
71. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
72. Thalidomide does not alter estrogen-progesterone hormone single dose pharmacokinetics
73. The metabolism of thalidomide: The spontaneous hydrolysis of thalidomide in solution
74. Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood
75. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative
76. Antitumor activity of thalidomide in refractory multiple myeloma
77. Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM)
78. Introduction to immunotherapy for multiple myeloma - Insights and advances
79. The pharmacology of thalidomide
80. Thalidomide and its impact in dermatology
81. Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers
82. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation
83. Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: Interaction with oral hexachlorobenzene
84. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses
85. Binding of thalidomide to 1-acid glycoprotein may be involved in its inhibition of TNF production
86. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
87. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells
88. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
89. Bone marrow angiogenesis and progression in multiple myeloma
90. Thalidomide with dexamethasone for resistant multiple myeloma
91. Induction of drug metabolism in the rat by taglutimide, a sedative- hypnotic glutarimide derivative
92. TM: A comprehensive program for controlling and monitoring access to thalidomide